506 related articles for article (PubMed ID: 31220725)
1. Direct monitoring of breast and endometrial cancer cell epigenetic response to DNA methyltransferase and histone deacetylase inhibitors.
Teixeira SR; Abreu CM; Parkes L; Davies J; Yao S; Sawhney MA; Margarit L; Gonzalez D; Pinto IM; Francis LW; Conlan RS
Biosens Bioelectron; 2019 Sep; 141():111386. PubMed ID: 31220725
[TBL] [Abstract][Full Text] [Related]
2. Treatment of buffalo (Bubalus bubalis) donor cells with trichostatin A and 5-aza-2'-deoxycytidine alters their growth characteristics, gene expression and epigenetic status and improves the in vitro developmental competence, quality and epigenetic status of cloned embryos.
Saini M; Selokar NL; Agrawal H; Singla SK; Chauhan MS; Manik RS; Palta P
Reprod Fertil Dev; 2016 Apr; 28(6):824-37. PubMed ID: 25409339
[TBL] [Abstract][Full Text] [Related]
3. The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells.
Zhu WG; Otterson GA
Curr Med Chem Anticancer Agents; 2003 May; 3(3):187-99. PubMed ID: 12769777
[TBL] [Abstract][Full Text] [Related]
4. Epigenetics and miRNA as predictive markers and targets for lung cancer chemotherapy.
El-Awady RA; Hersi F; Al-Tunaiji H; Saleh EM; Abdel-Wahab AH; Al Homssi A; Suhail M; El-Serafi A; Al-Tel T
Cancer Biol Ther; 2015; 16(7):1056-70. PubMed ID: 25962089
[TBL] [Abstract][Full Text] [Related]
5. Cytostatic and apoptotic effects of DNMT and HDAC inhibitors in endometrial cancer cells.
Xu S; Ren J; Chen HB; Wang Y; Liu Q; Zhang R; Jiang SW; Li J
Curr Pharm Des; 2014; 20(11):1881-7. PubMed ID: 23888960
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic Regulatory Mechanisms Induced by Resveratrol.
Fernandes GFS; Silva GDB; Pavan AR; Chiba DE; Chin CM; Dos Santos JL
Nutrients; 2017 Nov; 9(11):. PubMed ID: 29104258
[TBL] [Abstract][Full Text] [Related]
7. Unique methylation pattern of oncostatin m receptor gene in cancers of colorectum and other digestive organs.
Deng G; Kakar S; Okudiara K; Choi E; Sleisenger MH; Kim YS
Clin Cancer Res; 2009 Mar; 15(5):1519-26. PubMed ID: 19223499
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma.
Venturelli S; Armeanu S; Pathil A; Hsieh CJ; Weiss TS; Vonthein R; Wehrmann M; Gregor M; Lauer UM; Bitzer M
Cancer; 2007 May; 109(10):2132-41. PubMed ID: 17407132
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional Selectivity of Epigenetic Therapy in Cancer.
Sato T; Cesaroni M; Chung W; Panjarian S; Tran A; Madzo J; Okamoto Y; Zhang H; Chen X; Jelinek J; Issa JJ
Cancer Res; 2017 Jan; 77(2):470-481. PubMed ID: 27879268
[TBL] [Abstract][Full Text] [Related]
10. Change in gene expression profiles of secreted frizzled-related proteins (SFRPs) by sodium butyrate in gastric cancers: induction of promoter demethylation and histone modification causing inhibition of Wnt signaling.
Shin H; Kim JH; Lee YS; Lee YC
Int J Oncol; 2012 May; 40(5):1533-42. PubMed ID: 22246241
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic Treatment Options in Urothelial Carcinoma.
Pinkerneil M; Hoffmann MJ; Niegisch G
Methods Mol Biol; 2018; 1655():289-317. PubMed ID: 28889393
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors.
Schneider-Stock R; Ocker M
IDrugs; 2007 Aug; 10(8):557-61. PubMed ID: 17665331
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of DNA Methylation and Histone Deacetylation as Epigenetically Active Drugs for Anticancer Therapy.
Myasoedova VA; Sukhorukov V; Grechko AV; Zhang D; Romanenko E; Orekhov V; Orekhov AN
Curr Pharm Des; 2019; 25(6):635-641. PubMed ID: 30950345
[TBL] [Abstract][Full Text] [Related]
15. Treatment of cardiovascular pathology with epigenetically active agents: Focus on natural and synthetic inhibitors of DNA methylation and histone deacetylation.
Chistiakov DA; Orekhov AN; Bobryshev YV
Int J Cardiol; 2017 Jan; 227():66-82. PubMed ID: 27852009
[TBL] [Abstract][Full Text] [Related]
16. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine.
Keen JC; Yan L; Mack KM; Pettit C; Smith D; Sharma D; Davidson NE
Breast Cancer Res Treat; 2003 Oct; 81(3):177-86. PubMed ID: 14620913
[TBL] [Abstract][Full Text] [Related]
17. Troglitazone inhibits histone deacetylase activity in breast cancer cells.
Davies GF; Ross AR; Arnason TG; Juurlink BH; Harkness TA
Cancer Lett; 2010 Feb; 288(2):236-50. PubMed ID: 19699029
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications.
Hellebrekers DM; Castermans K; Viré E; Dings RP; Hoebers NT; Mayo KH; Oude Egbrink MG; Molema G; Fuks F; van Engeland M; Griffioen AW
Cancer Res; 2006 Nov; 66(22):10770-7. PubMed ID: 17108113
[TBL] [Abstract][Full Text] [Related]
19. Promoter histone H3 lysine 9 di-methylation is associated with DNA methylation and aberrant expression of p16 in gastric cancer cells.
Meng CF; Zhu XJ; Peng G; Dai DQ
Oncol Rep; 2009 Nov; 22(5):1221-7. PubMed ID: 19787243
[TBL] [Abstract][Full Text] [Related]
20. Dual targeting of epigenetic therapy in cancer.
Hellebrekers DM; Griffioen AW; van Engeland M
Biochim Biophys Acta; 2007 Jan; 1775(1):76-91. PubMed ID: 16930846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
